Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019.
ABSSSI
CABP
MRSA
Omadacycline
Surveillance
Journal
Journal of global antimicrobial resistance
ISSN: 2213-7173
Titre abrégé: J Glob Antimicrob Resist
Pays: Netherlands
ID NLM: 101622459
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
02
02
2021
revised:
13
09
2021
accepted:
15
09
2021
pubmed:
15
11
2021
medline:
31
12
2021
entrez:
14
11
2021
Statut:
ppublish
Résumé
Omadacycline was tested against 7000 bacterial isolates collected prospectively from medical centres in the USA during 2019. Antimicrobial susceptibility testing was performed according to Clinical and Laboratory Standards Institute (CLSI) guidelines. Omadacycline was active against: Staphylococcus aureus (MIC The 2019 in vitro activity of omadacycline against key Gram-positive and Gram-negative pathogens has not changed compared with the prior 3 years of surveillance in the SENTRY Antimicrobial Surveillance Program. Omadacycline merits further study in serious infections where resistant pathogens may be encountered.
Identifiants
pubmed: 34775129
pii: S2213-7165(21)00235-6
doi: 10.1016/j.jgar.2021.09.011
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Tetracyclines
0
omadacycline
090IP5RV8F
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
337-351Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.